Linerixibat Long-term Safety and Tolerability Study (LLSAT)

Enrolling By Invitation

99 years or below

All

Phase N/A

1 Location

Brief description of study

Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants with Primary Biliary Cholangitis

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

TBD

Updated on 13 Nov 2024. Study ID: 856172

If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com